J. A. Johnson

3.5k total citations · 1 hit paper
59 papers, 2.4k citations indexed

About

J. A. Johnson is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, J. A. Johnson has authored 59 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Cardiology and Cardiovascular Medicine, 12 papers in Pulmonary and Respiratory Medicine and 12 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in J. A. Johnson's work include Renin-Angiotensin System Studies (17 papers), Blood Pressure and Hypertension Studies (9 papers) and Hormonal Regulation and Hypertension (9 papers). J. A. Johnson is often cited by papers focused on Renin-Angiotensin System Studies (17 papers), Blood Pressure and Hypertension Studies (9 papers) and Hormonal Regulation and Hypertension (9 papers). J. A. Johnson collaborates with scholars based in United States, Israel and United Kingdom. J. A. Johnson's co-authors include James O. Davis, Teri E. Klein, Stuart A. Scott, J. Glenn Morris, A C Wright, Robert T. Witty, Alan R. Shuldiner, Catherine M. Stein, Jean‐Sébastien Hulot and D M Roden and has published in prestigious journals such as Science, Journal of Clinical Investigation and Circulation Research.

In The Last Decade

J. A. Johnson

57 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing

2011 473 citations J. A. Johnson, Li Gong et al. Clinical Pharmacology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. A. Johnson United States	22	620	587	534	401	379	59	2.4k
Taimour Langaee United States	37	1.0k 1.6×	2.5k 4.3×	82 0.2×	1.5k 3.7×	1.2k 3.1×	152	5.5k
Hanne Rolighed Christensen Denmark	14	205 0.3×	90 0.2×	49 0.1×	417 1.0×	161 0.4×	55	1.6k
Pierre N.M. Demacker Netherlands	51	1.3k 2.1×	114 0.2×	191 0.4×	1.3k 3.2×	2.8k 7.4×	169	7.8k
Shitalben Patel United States	22	170 0.3×	677 1.2×	84 0.2×	222 0.6×	266 0.7×	66	1.5k
Shigeru Miyazaki Japan	33	184 0.3×	110 0.2×	31 0.1×	684 1.7×	402 1.1×	185	3.4k
Douglas L. Schmucker United States	32	110 0.2×	606 1.0×	25 0.0×	701 1.7×	139 0.4×	64	3.0k
Hans Ericsson Sweden	23	361 0.6×	157 0.3×	20 0.0×	291 0.7×	163 0.4×	71	1.5k
Θωμάς Τσαγανός Greece	20	164 0.3×	62 0.1×	79 0.1×	562 1.4×	116 0.3×	66	3.5k
Philippe Lettéron France	41	91 0.1×	1.1k 1.9×	24 0.0×	1.4k 3.4×	483 1.3×	71	5.0k
Daniela Ceccarelli Italy	33	43 0.1×	146 0.2×	953 1.8×	891 2.2×	42 0.1×	84	3.2k

Countries citing papers authored by J. A. Johnson

Since Specialization

Citations

This map shows the geographic impact of J. A. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. A. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. A. Johnson more than expected).

Fields of papers citing papers by J. A. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. A. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. A. Johnson. The network helps show where J. A. Johnson may publish in the future.

Co-authorship network of co-authors of J. A. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of J. A. Johnson. A scholar is included among the top collaborators of J. A. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. A. Johnson. J. A. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Del‐Aguila, Jorge L., Rhonda M. Cooper‐DeHoff, Arlene B. Chapman, et al.. (2014). Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide. The Pharmacogenomics Journal. 15(2). 153–157. 6 indexed citations

Wang, Ying, J. A. Johnson, Francis G. Spinale, Michael A. Sutton, & Susan M. Lessner. (2013). Quantitative Measurement of Dissection Resistance in Intimal and Medial Layers of Human Coronary Arteries. Experimental Mechanics. 54(4). 677–683. 21 indexed citations

Johnson, J. A., Li Gong, Michelle Whirl‐Carrillo, et al.. (2011). Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing. Clinical Pharmacology & Therapeutics. 90(4). 625–629. 473 indexed citations breakdown →

Scott, Stuart A., Katrin Sangkuhl, Catherine M. Stein, et al.. (2011). Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Clinical Pharmacology & Therapeutics. 90(2). 328–332. 362 indexed citations

Turner, S. T., G. L. Schwartz, Arlene B. Chapman, et al.. (2010). Plasma Renin Activity Predicts Blood Pressure Responses to -Blocker and Thiazide Diuretic as Monotherapy and Add-On Therapy for Hypertension. American Journal of Hypertension. 23(9). 1014–1022. 58 indexed citations

Johnson, J. A., Yan Gong, R COOPERDEHOFF, et al.. (2009). Hydrochlorothiazide and Atenolol Combination Antihypertensive Therapy: Effects of Drug Initiation Order. Clinical Pharmacology & Therapeutics. 86(5). 533–539. 15 indexed citations

Abou-Mohamed, G., J. A. Johnson, Liming Jin, et al.. (2004). Roles of Superoxide, Peroxynitrite, and Protein Kinase C in the Development of Tolerance to Nitroglycerin. Journal of Pharmacology and Experimental Therapeutics. 308(1). 289–299. 44 indexed citations

Kelly, Louise, David L. Smith, Emma Snary, et al.. (2004). Animal growth promoters: to ban or not to ban?. International Journal of Antimicrobial Agents. 24(3). 205–212. 43 indexed citations

Johnson, J. A.. (2002). Pharmacogenetics of cardiovascular drugs. Briefings in Functional Genomics and Proteomics. 1(1). 66–79. 9 indexed citations

10.

Harris, Anthony, David L. Smith, J. A. Johnson, Douglas D. Bradham, & Mary‐Claire Roghmann. (2002). Risk Factors for Imipenem-Resistant Pseudomonas aeruginosa among Hospitalized Patients. Clinical Infectious Diseases. 34(3). 340–345. 146 indexed citations

11.

Franco, Augusto A., Alan Fix, Ana Prada, et al.. (1997). Cholera in Lima, Peru, Correlates with Prior Isolation of Vibrio cholerae from the Environment. American Journal of Epidemiology. 146(12). 1067–1075. 60 indexed citations

12.

Morris, J. Glenn, et al.. (1995). Clinical and Immunologic Characteristics of Vibrio cholerae O139 Bengal Infection in North American Volunteers. The Journal of Infectious Diseases. 171(4). 903–908. 53 indexed citations

13.

Comstock, Laurie E., David R. Maneval, Pinaki Panigrahi, et al.. (1995). The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infection and Immunity. 63(1). 317–323. 74 indexed citations

14.

Johnson, J. A., et al.. (1994). Pressor responsiveness in rats with hypertension induced by mestranol. Contraception. 50(4). 383–389. 1 indexed citations

15.

Johnson, J. A., et al.. (1994). Effect on Pressor and Vascular Responsiveness in Rabbits of Drugs That Decrease Norepinephrine Uptake. Experimental Biology and Medicine. 206(4). 375–383. 2 indexed citations

16.

Johnson, J. A., et al.. (1993). Arterial sodium concentration in rats with hypertension induced by mestranol. Contraception. 48(1). 71–79. 1 indexed citations

17.

Bell, M. E., Charles E. Wood, Maureen Keller‐Wood, et al.. (1991). Influence of reproductive state on pituitary-adrenal activity in the ewe. Domestic Animal Endocrinology. 8(2). 245–254. 66 indexed citations

18.

Johnson, J. A., et al.. (1989). Total Exchangeable Sodium in Rats with Mestranol-Induced Hypertension. Experimental Biology and Medicine. 191(1). 43–46. 2 indexed citations

19.

Johnson, J. A., et al.. (1983). Pressor responses to norepinephrine during captopril in renal prehypertensive rabbits.. Hypertension. 5(2). 159–165. 16 indexed citations

20.

Johnson, J. A. & James O. Davis. (1973). Angiotensin II: Important Role in the Maintenance of Arterial Blood Pressure. Science. 179(4076). 906–907. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact